PD-L1 protein expression measured by the SP263 immunohistochemistry (IHC) assay is a well-established predictive biomarker for immune checkpoint inhibitor therapy. SP263, performed on the Ventana platform, reports the proportion of tumor cells with membrane staining using a tumor proportion score (TPS). Increasingly, clinics combine PD-L1 results with broader molecular data to build a fuller picture of likely treatment response. This article examines how SP263 testing integrates with other biomarkers in a combination strategy.
PD-L1 expression is only one axis of immune response. A comprehensive approach often pairs SP263 with next-generation sequencing that reports tumor mutational burden (TMB) and microsatellite instability (MSI), because each marker captures a different mechanism of immune visibility. Used together, these tests help distinguish tumors that are more likely to respond to checkpoint blockade from those that may need alternative or combined pathways.
When a patient already has a comprehensive genomic profile, adding SP263 avoids redundant tissue use by layering protein-level evidence on top of DNA-level findings. The IHC result is reported alongside variant data so that therapy selection weighs both targetable drivers and immune context. This layered reporting is especially useful in tumors where PD-L1 status and driver alterations can coexist.
PD-L1 scoring is platform and clone dependent, so the assay used should match the therapeutic context. SP263 and the 22C3 assay show high concordance in several tumor types, yet cut-offs and platforms differ. Pathology teams should apply the scoring system validated for the intended therapy and document the assay clone in the report to preserve comparability across visits.
A practical workflow is to order SP263 at the same time as the NGS panel whenever immunotherapy is a realistic option. Coordinated ordering avoids a second biopsy and aligns reporting timelines, so the care team receives immune and genomic evidence together. Laboratories that flag the assay clone and scoring system on every report make this combined interpretation straightforward to audit and repeat.
Q: What does the SP263 assay measure? A: It measures PD-L1 protein on tumor cell membranes by IHC and reports a tumor proportion score based on the percentage of stained viable tumor cells.
Q: Should SP263 replace genomic testing? A: No. It complements NGS by adding protein-level immune context; the two provide different but overlapping information.
Q: Is SP263 interchangeable with other PD-L1 assays? A: Studies show strong concordance with assays like 22C3, but scoring platforms and cut-offs differ, so the intended therapy should guide assay choice.
Q: Why combine PD-L1 with TMB or MSI? A: Each marker reflects a distinct mechanism of immune responsiveness, and combining them gives a more complete basis for treatment decisions.
PD-L1 protein expression measured by the SP263 immunohistochemistry (IHC) assay is a well-established predictive biomarker for immune checkpoint inhibitor therapy. SP263, performed on the Ventana platform, reports the proportion of tumor cells with membrane staining using a tumor proportion score (TPS). Increasingly, clinics combine PD-L1 results with broader molecular data to build a fuller picture of likely treatment response. This article examines how SP263 testing integrates with other biomarkers in a combination strategy.
PD-L1 expression is only one axis of immune response. A comprehensive approach often pairs SP263 with next-generation sequencing that reports tumor mutational burden (TMB) and microsatellite instability (MSI), because each marker captures a different mechanism of immune visibility. Used together, these tests help distinguish tumors that are more likely to respond to checkpoint blockade from those that may need alternative or combined pathways.
When a patient already has a comprehensive genomic profile, adding SP263 avoids redundant tissue use by layering protein-level evidence on top of DNA-level findings. The IHC result is reported alongside variant data so that therapy selection weighs both targetable drivers and immune context. This layered reporting is especially useful in tumors where PD-L1 status and driver alterations can coexist.
PD-L1 scoring is platform and clone dependent, so the assay used should match the therapeutic context. SP263 and the 22C3 assay show high concordance in several tumor types, yet cut-offs and platforms differ. Pathology teams should apply the scoring system validated for the intended therapy and document the assay clone in the report to preserve comparability across visits.
A practical workflow is to order SP263 at the same time as the NGS panel whenever immunotherapy is a realistic option. Coordinated ordering avoids a second biopsy and aligns reporting timelines, so the care team receives immune and genomic evidence together. Laboratories that flag the assay clone and scoring system on every report make this combined interpretation straightforward to audit and repeat.
Q: What does the SP263 assay measure? A: It measures PD-L1 protein on tumor cell membranes by IHC and reports a tumor proportion score based on the percentage of stained viable tumor cells.
Q: Should SP263 replace genomic testing? A: No. It complements NGS by adding protein-level immune context; the two provide different but overlapping information.
Q: Is SP263 interchangeable with other PD-L1 assays? A: Studies show strong concordance with assays like 22C3, but scoring platforms and cut-offs differ, so the intended therapy should guide assay choice.
Q: Why combine PD-L1 with TMB or MSI? A: Each marker reflects a distinct mechanism of immune responsiveness, and combining them gives a more complete basis for treatment decisions.
english
français
Deutsch
Italiano
Русский
Español
português
Nederlandse
ελληνικά
日本語
한국
العربية
हिन्दी
Türkçe
indonesia
tiếng Việt
ไทย
বাংলা
فارسی
polski
